🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

95 results for “Base” Clear

  1. ASCAPE-based follow-up strategy

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer

    phase 2 other active

    1 trial

  2. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  3. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  4. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  5. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  6. CMV-pp65 CTLs

    Evidence Based Cataract Study Group

    Cytomegalovirus

    phase 2 mab completed

    1 trial

  7. Computer-based Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  8. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  9. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  10. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  11. Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  12. FINGER 2.0 multidomain lifestyle-based intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cognitive Decline

    phase 2 other active

    1 trial

  13. FOLFOXIRI-based HAIC+Fuquinitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Neoplasms

    phase 2 small molecule completed

    1 trial

  14. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  15. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  16. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  17. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  18. Mindfulness Based Relapse Prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  19. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. Routine Template-based lymphadenectomy

    The First People's Hospital of Lianyungang

    Lymph Node Dissection

    phase 2 other active

    1 trial

  21. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  22. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  23. Tabelecleucel

    Evidence Based Cataract Study Group

    Nasopharyngeal Carcinoma

    phase 2 mab terminated

    1 trial

  24. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources